Adverum Biotechnologies (Nasdaq: ADVM) is a clinical-stage gene therapy company targeting unmet medical needs for serious ocular and rare diseases. Adverum is evaluating its novel gene therapy candidate, ADVM-022, as a one-time, intravitreal injection for the treatment of its lead indication, wet age-related macular degeneration.

Biotechnology

Adverum Biotech

Laurent Fischer

Senior Director, Global Commerical Strategy

Joanna D.

Adam Turpcu

Rabia Gurses Ozden

Romuald Corbau

R. Andrew Ramelmeier

Bill Tan

Linda Rubinstein

Star Seyedkazemi

Dena House

John Rakow

Heikki Jouttijärvi

Kishor Peter Soparkar

Carla Fiankan

The Clinical Operations team at Adverum Biotech manages and oversees the execution of clinical trials for the company's gene therapy candidates. This includes coordinating clinical development, data management, and contracts to ensure trials are conducted efficiently, comply with regulatory requirements, and generate reliable data to support the development of treatments like ADVM-022 for serious ocular and rare diseases.

Clinical Operations

Corporate Affairs

Leadership Team

Scientific Team

Clinical Operations

About

Team members

Other teams at Adverum Biotech

Corporate Affairs

Leadership Team

Scientific Team